News

Stories

See all

Living With Osteoarthritis: The Importance of Being Heard

View Story

Your COVID-19 Treatment Journey: Our Antibodies Might Help

View Story

Consent forms for Jonee Drake (Lilly employee) and son Carter are located in CAR.

'A Day On – Not a Day Off': Honoring Dr. Martin Luther King Jr.’s Legacy

View Story

Updates: Lilly's Global COVID-19 Response

View Story

Time to Tear Down the Rebate Wall

View Story

Digital Health: Partnering to Improve Outcomes

View Story


Press Releases

See all

Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement

January 15, 2021

Tags |  Financial

INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the




Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund

January 15, 2021

Tags |  Corporate

Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP




Gabrielle Sulzberger Elected to Lilly Board of Directors

January 14, 2021

Tags |  Corporate

INDIANAPOLIS , Jan. 14, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021 . As a member of Lilly 's board, she will serve on both the Audit Committee and the Ethics and Compliance Committee .




US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

January 11, 2021

Tags |  Product

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death